6-O-Methyl-galactose | 10287-49-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-O-Methyl-galactose
• 英文别名: 6-(Methoxymethyl)oxane-2,3,4,5-tetrol
• CAS: 10287-49-7；14199-58-7；24436-14-4；27552-12-1；31505-26-7；31505-27-8；31505-28-9；31505-29-0；87936-86-5；87936-87-6
• 化学式: C₇H₁₄O₆
• 分子量: 194.185
• InChiKey: QWJKEQVWXSYDJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  99.4
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] N-HYDROXYFORMAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THEM FOR USE AS BMP1, TLL1 AND/OR TLL2 INHIBITORS<br/>[FR] COMPOSÉS N-HYDROXYFORMAMIDES ET COMPOSITIONS LES COMPRENANT POUR UNE UTILISATION COMME INHIBITEURS DE BMP1, TLL1 ET/OU TLL2
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017006296A1

  公开（公告）日：2017-01-12

  Compounds of Formulas (I) and (II) and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

  公式（I）和（II）的化合物及其盐；制备和使用这些化合物的方法，包括用于抑制BMP1、TLL1和/或TLL2以及治疗与BMP1、TLL1和/或TLL2活性相关的疾病的用途。
• [EN] INHIBITORS OF ALDOSE REDUCTASE<br/>[FR] INHIBITEURS DE L'ALDOSE RÉDUCTASE
  申请人：APPLIED THERAPEUTICS INC

  公开号：WO2020205846A1

  公开（公告）日：2020-10-08

  The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

  本公开涉及新颖化合物及其药物组合物，以及促进皮肤健康老化、治疗皮肤疾病、心血管疾病、肾脏疾病、血管生成障碍（如癌症）、组织损伤治疗（如非心脏组织损伤）、心肌梗死演变治疗、缺血性损伤治疗以及利用本发明的化合物和组合物治疗糖尿病引起的并发症等方法。其他疾病可能包括但不限于动脉粥样硬化、心肌病、冠状动脉疾病、糖尿病肾病、糖尿病神经病变、糖尿病视网膜病变、糖尿病心肌病、皮肤感染、外周血管疾病、中风、半乳糖血症、哮喘、PMM2-CDG等。
• Transition Metal-Catalyzed Synthesis of Dendritic Polymers
  申请人：Guan Zhibin

  公开号：US20080306229A1

  公开（公告）日：2008-12-11

  Dendritic amphiphilic polymers are contemplated. Most preferably, such polymers will be fabricated in a single step to the final product that may further be derivatized with, among others, biological relevant molecules. In alternative aspects, precursors of such molecules are prepared in a single step, and the precursors are then reacted to the dendritic amphiphilic polymers.

  考虑使用树突状的两性分子聚合物。最好的情况是，这样的聚合物将在单步骤中制成最终产品，该产品可以进一步衍生出生物相关分子，其中包括生物相关分子。在另一方面，这些分子的前体物可以在单步骤中制备，然后将前体物反应到树突状的两性分子聚合物中。
• AGENTS FOR MODULATION OF WNT-TCF SIGNALLING AND USES THEREOF
  申请人：UNIVERSITE DE GENEVE

  公开号：EP3248604A1

  公开（公告）日：2017-11-29

  The present invention relates to inhibitors of WNT-TCF signalling and compositions thereof. The invention further relates to use of those inhibitors of WNT-TCF signalling and compositions thereof for the treatment and/or prevention and/or prevention of recurrence of a WNT-activated cancer and/or a cancer associated with the cancer stem cells. the active compounds are certain cardenolides and bufanolides.

  本发明涉及WNT-TCF信号的抑制剂及其组合物。本发明还涉及将这些 WNT-TCF 信号抑制剂及其组合物用于治疗和/或预防和/或防止 WNT 激活的癌症和/或与癌症干细胞相关的癌症复发。
• Steviol glycosides, their compositions and their purification
  申请人：The Coca-Cola Company

  公开号：US10570164B2

  公开（公告）日：2020-02-25

  The present invention relates generally to steviol glycosides, as well as compositions comprising such steviol glycosides. The present invention further extends to methods of preparing and purifying such steviol glycosides and methods for enhancing the flavor or sweetness of consumables using these steviol glycosides and compositions. The present invention extends to consumables comprising steviol glycosides, where the such steviol glycosides are present in a concentration at or below their sweetness recognition threshold, and wherein such steviol glycosides enhance the sweetness of the consumable.

  本发明一般涉及甜菊醇糖苷以及包含这种甜菊醇糖苷的组合物。本发明进一步延伸至制备和纯化此类甜菊醇糖苷的方法，以及使用这些甜菊醇糖苷和组合物增强消费品风味或甜度的方法。本发明延伸至包含甜菊醇糖苷的消费品，其中甜菊醇糖苷的浓度达到或低于甜味识别阈值，并且甜菊醇糖苷增强了消费品的甜味。